IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-50802-2.html
   My bibliography  Save this article

Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial

Author

Listed:
  • Qianqian Xin

    (Sinovac Life Sciences Co., Ltd.)

  • Kaiqin Wang

    (National Institutes for Food and Drug Control)

  • Teck-Hock Toh

    (Sibu Hospital, Ministry of Health Malaysia)

  • Yue Yuan

    (Sinovac Life Sciences Co., Ltd.)

  • Xing Meng

    (Sinovac Biotech Co., Ltd.)

  • Zhiwei Jiang

    (Beijing KEY TECH Statistical Technology Co., Ltd.)

  • Hengming Zhang

    (Sinovac Biotech Co., Ltd.)

  • Jinye Yang

    (Sinovac Life Sciences Co., Ltd.)

  • Huijie Yang

    (National Institutes for Food and Drug Control)

  • Gang Zeng

    (Sinovac Biotech Co., Ltd.)

Abstract

Safe and effective vaccines against COVID-19 for children and adolescents are needed. This international multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial assessed the efficacy, immunogenicity, and safety of CoronaVac® in children and adolescents (NCT04992260). The study was carried out in Chile, South Africa, Malaysia, and the Philippines. The enrollment ran from September 10, 2021 to March 25, 2022. For efficacy assessment, the median follow-up duration from 14 days after the second dose was 169 days. A total of 11,349 subjects were enrolled. Two 3-μg injections of CoronaVac® or placebo were given 28 days apart. The primary endpoint was the efficacy of the CoronaVac®. The secondary endpoints were the immunogenicity and safety. The vaccine efficacy was 21.02% (95% CI: 1.65, 36.67). The level of neutralizing antibody in the vaccine group was significantly higher than that in the placebo group (GMT: 390.80 vs. 62.20, P

Suggested Citation

  • Qianqian Xin & Kaiqin Wang & Teck-Hock Toh & Yue Yuan & Xing Meng & Zhiwei Jiang & Hengming Zhang & Jinye Yang & Huijie Yang & Gang Zeng, 2024. "Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial," Nature Communications, Nature, vol. 15(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-50802-2
    DOI: 10.1038/s41467-024-50802-2
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-50802-2
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-50802-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-50802-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.